Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Operations: 2010-2025

Historic Cash from Operations for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $179.6 million.

  • Arrowhead Pharmaceuticals' Cash from Operations rose 114.93% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.6 million, marking a year-over-year increase of 138.79%. This contributed to the annual value of $179.6 million for FY2025, which is 138.79% up from last year.
  • According to the latest figures from FY2025, Arrowhead Pharmaceuticals' Cash from Operations is $179.6 million, which was up 138.79% from -$462.9 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year Cash from Operations high stood at $179.6 million for FY2025, and its period low was -$462.9 million during FY2024.
  • Moreover, its 3-year median value for Cash from Operations was -$153.9 million (2023), whereas its average is -$145.7 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Cash from Operations spiked by 278.82% in 2021 and then plummeted by 200.77% in 2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Cash from Operations (Yearly) stood at $171.3 million in 2021, then crashed by 179.46% to -$136.1 million in 2022, then dropped by 13.05% to -$153.9 million in 2023, then tumbled by 200.77% to -$462.9 million in 2024, then surged by 138.79% to $179.6 million in 2025.